Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to establish Consortia for HIV/AIDS Vaccine Development (CHAVD) to support a coordinated, multidisciplinary team(s) of researchers focused on iterative approaches to accelerate HIV vaccine development by addressing key immunogen design roadblocks to the discovery and development of a safe and effective antibody-mediated preventive HIV vaccine.

The purpose of this funding opportunity is to conduct activities to promote and support vaccination services within the pharmacy setting. Activities include, but are not limited to: - Education/Outreach to pharmacists about current pediatric, adolescent, and adult immunization recommendations and proper vaccine administration - Facilitation of communication and exchange of information between pharmacists and providers and public health programs -Quality Improvement efforts -Improved immunization documentation through use of immunization information systems and data sharing -Coordination with public health preparedness and immunization programs to establish formalized agreements for pandemic vaccine program readiness and response By the end of the project, the awardee is expected to disseminate and promote best practices/successes to a national audience of healthcare providers, including both pharmacists and other healthcare providers.

This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), invites research applications for projects that support preclinical development of lead candidate therapeutics, vaccines and related technologies, or diagnostics against NIAID Category A, B, or C priority agents. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

WHO CAN APPLY? I-Corps@Ohio funds will be offered on a competitive basis to teams of faculty researchers and graduate students developing institution-based technologies from Ohio colleges and universities. Under the supervision of business and entrepreneurial mentors, teams will develop market-driven value propositions and scalable business models around their technologies and attract follow on funding to support company formation and market entry. APPLICATION PROCESS The I-Corps@Ohio proposal submission process consists of five steps: 1. mandatory meeting with the appropriate TTO representative(s) at the PI's institution; 2. team selection of technology track (science and engineering or medtech); 3. registration of all team members in the online portal; 4. proposal submission; and 5. full team interview with I-Corps@Ohio program representatives. All teams are required to complete the online profile and submission questionnaire beginning October 23, 2019. Deadline to apply is January 15, 2019. The PI may complete this information or designate another member of the team as the lead member. Subsequent members of the team will be invited to join by the lead member through the application portal and must complete his or her profile. Every effort should be made to identify all team members prior to submitting the online proposal submission questionnaire. Additional team members may be added later. You will be asked to select from two tracks: Medtech Track: Teams will select Medtech Track if the subject technology is in the form of medical devices, diagnostics, medicines, vaccines, software, testing procedures and systems and is developed to solve a health/clinical problem and improve the quality of human life. Science and Engineering (S&E) Track: Teams will select S&E Track if the technology does not fit into the Medtech category.